*ViiV Healthcare Employees receive 100% of GSK's Total Rewards and Benefits
There are currently 200,000 people taking PrEP as an option in the US. The US Government believes that 1.2 million people would benefit from PrEP if they were at risk of becoming HIV positive and has a goal to reduce annual infections (38,000) by 75% by 2025 and 90% by 2030. While there are 38,000 new cases in the US annually, globally, there are 1.7M. In the US and the developed world, the challenge is largely a function of stigma that men who have sex with men experience; conversely, in places like Africa, the population most at risk is adolescents, girls and young women with a different set of challenges. With such a such a significant gap between those treated and those believed to benefit, there is a compelling opportunity for new innovation such as cabotegravir long-acting for prevention of HIV.
As the first injectable regimen for pre exposure prophylaxis for people at risk for HIV, this will require a significant change in approach by providers to integrate into their service delivery models. Moreover, a significant shift in mindset is needed with consumers to create action. This role will need to create innovative/disruptive content, tools and resources to create awareness and adoption by HCPs and consumers across the customer journey.
The Global Marketing Director Cab PrEP Content Strategy will begin work with the US to diagnosis and develop solutions for providers, people at risk of HIV, and public health entities, codifying the process for application to other LOCs, and supporting with LOC activation activities.
Reporting to the lead Global marketing director for Cabotegravir PrEP, the GMD will influence and work collaboratively with internal stakeholders and agency/vendor partners to lead the development of innovative content strategies and tactics, early focus on US with expectation to adapt to other markets to enable activation of the global launch plan. This includes: market analyses, competitive benchmarking, deep customer insight gathering and the development of the tactical plan and innovative programs.
Contribute to a culture of “One Team”, driving organizational continuity and alignment across LOCs while seeking feedback and sharing best practices to deliver the global launch plan
Competitive intelligence lead, staying abreast of competitive strategies and tactics to ensure content, tools and resources competitively position the brand
Manage partner agency relationships, workflow, and related expense budgets
Partner with regulatory, medical, compliance and legal through the development and approval phases to ensure all claims, content, and materials are held to the highest standards while competitively positioning the brand and addressing customer needs
Innovative patient support program development to meet the unique challenges (marginalized or discriminated populations who experience significant stigma) experienced by people living with HIV (PLWHIV) and at risk of contracting HIV.
Global content strategy and claims development in alignment with global launch plan deliverables to competitively position the brand and disrupt current HCP and consumer paradigms
Content Co-creation lead US/Priority markets
Identification and prioritization of opportunities and strategies based on current and future state customer (HCP and patient) journey and insights to deliver the launch plan
Working with a global agency on development of an innovative/disruptive Global Integrated Campaigns (personal/non-personal resource delivery) and other deliverables
Why ViiV Healthcare?
Our values and expectations are at the heart of everything we do and form an important part of our culture.
These include Patient focus, Transparency, Respect, Integrity along with Courage, Accountability, Development, and Teamwork. As GSK focuses on our values and expectations and a culture of innovation, performance, and trust, the successful candidate will demonstrate the following capabilities:
Agile and distributed decision-making – using evidence and applying judgement to balance pace, rigour and risk.
Managing individual and team performance.
Committed to delivering high quality results, overcoming challenges, focusing on what matters, execution.
Implementing change initiatives and leading change.
Sustaining energy and well-being, building resilience in teams.
Continuously looking for opportunities to learn, build skills and share learning both internally and externally.
Developing people and building a talent pipeline.
Translating strategy into action - a compelling narrative, motivating others, setting objectives and delegation.
Building strong relationships and collaboration, managing trusted stakeholder relationships internally and externally.
Budgeting and forecasting, commercial and financial acumen.
We are looking for professionals with these required skills to achieve our goals:
BA/BSc in Business, marketing, science or related discipline
Experience in utilizing research and market data to shape content strategies and tactics
Experience in brand marketing, including product launches, campaign development (personal and non-personal), and channel mix
Experience in patient/consumer orientation and delivery of innovative programs and tactics
Experience working with and managing external agencies
Experience in delivering innovative customer centric content plans, customer journeys and omni-channel marketing campaigns
Strong knowledge in content measurement methodologies, translating analytics into actionable insights and evaluating campaign performance across channels
If you have the following characteristics, it would be a plus:
Strong leadership and communication skills with demonstrated ability to work effectively in complex environments with ability to influence internal and external stakeholders to implement strategy
Graduate to Post Graduate Degree level (e.g. master, PhD) or equivalent experience
Successful product launch experience in a pharma marketing role
Global marketing experience
Experience delivering marketing campaigns in highly regulated environments
Knowledge of the pharma R&D process
Multicultural marketing experience
Employer will assist with relocation costs.
Internal Number: 261884
About ViiV Healthcare (GSK)
ViiV Healthcare is a global specialty HIV company, the only one that is 100% focused on researching and delivering new medicines for people living with, and at risk of, HIV. ViiV is highly mission-driven in our unrelenting commitment to being a trusted partner for all people living with and affected by HIV. Our aim is to think, act, and connect differently through a focus on education on and treatment for HIV. We go to extraordinary lengths to deliver the sorts of breakthroughs, both in treatments, care solutions and communities, that really count. We go beyond the boundaries of medicine by taking a holistic approach to HIV through developing and supporting sustainable community programs and improving access to care. We are fully committed to push through every challenge until HIV/AIDS is eradicated. ViiV has played a significant part in delivering breakthroughs that have turned HIV into a manageable health condition. We offer the largest portfolio of HIV medicines available anywhere, and we continue our work to cater for the widest possible range of needs in response to the HIV epidemic.
We are aware of how much is at stake for those affected by HIV and we show up every day 1...00% committed to the patients. Our work culture is fast-paced, diverse, inclusive, competitive, and caring. But ViiV isn’t just somewhere to work – it’s a place to belong, an invitation to bring your very best, and a team full of impact-driven team members who are hungry to make a difference.
While we have been improving lives of HIV patients for 30 years, this is an especially exciting time to be at ViiV, as we evaluate novel approaches to treatment and prevention that could further reduce the impact of HIV on individuals and communities.
ViiV Healthcare was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company. In 2012 Shionogi joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi.